Idera is developing novel TLR9 agonists for the treatment of infectious diseases.
TLR9 agonists are designed to selectively activate immune responses through TLR9, resulting in the induction of cytokines and activation of immune cells. In preclinical studies, our TLR9 agonists have been shown to induce multiple cytokines, including IFN-α.
Idera has conducted Phase 1 clinical trials of a TLR9 agonist, IMO-2125, in patients with chronic hepatitis C virus, or HCV, infection. These patients include both null-responders as well as treatment naive patients. The data from these Phase 1 studies showed that IMO-2125 administration was well tolerated and led to a reduction in HCV levels. This data was presented at EASL 2010 and AASLD 2010.